Your browser doesn't support javascript.
loading
High frequency and founder effect of the CYP3A4*20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme.
Apellániz-Ruiz, M; Inglada-Pérez, L; Naranjo, M E G; Sánchez, L; Mancikova, V; Currás-Freixes, M; de Cubas, A A; Comino-Méndez, I; Triki, S; Rebai, A; Rasool, M; Moya, G; Grazina, M; Opocher, G; Cascón, A; Taboada-Echalar, P; Ingelman-Sundberg, M; Carracedo, A; Robledo, M; Llerena, A; Rodríguez-Antona, C.
Affiliation
  • Apellániz-Ruiz M; Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Inglada-Pérez L; 1] Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain [2] ISCIII Center for Biomedical Research on Rare Diseases (CIBERER), Madrid, Spain.
  • Naranjo ME; CICAB Clinical Research Centre at Extremadura University Hospital and Medical School, Badajoz, Spain.
  • Sánchez L; Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Mancikova V; Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Currás-Freixes M; Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • de Cubas AA; Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Comino-Méndez I; Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Triki S; Research Group on Molecular and Cellular Screening Processes, Laboratory of Microorganisms and Biomolecules, Centre of Biotechnology of Sfax, Sfax, Tunisia.
  • Rebai A; Research Group on Molecular and Cellular Screening Processes, Laboratory of Microorganisms and Biomolecules, Centre of Biotechnology of Sfax, Sfax, Tunisia.
  • Rasool M; Center of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia.
  • Moya G; Pontificia Universidad Católica Argentina and Genos Laboratory, Buenos Aires, Argentina.
  • Grazina M; Faculty of Medicine CNC-Centre for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal.
  • Opocher G; Familial Cancer Clinic and Oncoendocrinology, Veneto Institute of Oncology, Padova, Italy.
  • Cascón A; 1] Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain [2] ISCIII Center for Biomedical Research on Rare Diseases (CIBERER), Madrid, Spain.
  • Taboada-Echalar P; Programa de Genética Humana, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Santiago, Chile.
  • Ingelman-Sundberg M; Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
  • Carracedo A; 1] Center of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia [2] Fundación Pública de Medicina Xenómica-SERGAS, Grupo de Medicina Xenómica, CIBERER, IDIS, Santiago de Compostela, Spain.
  • Robledo M; 1] Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain [2] ISCIII Center for Biomedical Research on Rare Diseases (CIBERER), Madrid, Spain.
  • Llerena A; CICAB Clinical Research Centre at Extremadura University Hospital and Medical School, Badajoz, Spain.
  • Rodríguez-Antona C; 1] Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain [2] ISCIII Center for Biomedical Research on Rare Diseases (CIBERER), Madrid, Spain.
Pharmacogenomics J ; 15(3): 288-92, 2015 Jun.
Article in En | MEDLINE | ID: mdl-25348618
ABSTRACT
Cytochrome P450 3A4 (CYP3A4) is a key drug-metabolizing enzyme. Loss-of-function variants have been reported as rare events, and the first demonstration of a CYP3A4 protein lacking functional activity is caused by CYP3A4*20 allele. Here we characterized the world distribution and origin of CYP3A4*20 mutation. CYP3A4*20 was determined in more than 4000 individuals representing different populations, and haplotype analysis was performed using CYP3A polymorphisms and microsatellite markers. CYP3A4*20 allele was present in 1.2% of the Spanish population (up to 3.8% in specific regions), and all CYP3A4*20 carriers had a common haplotype. This is compatible with a Spanish founder effect and classifies CYP3A4 as a polymorphic enzyme. This constitutes the first description of a CYP3A4 loss-of-function variant with high frequency in a population. CYP3A4*20 results together with the key role of CYP3A4 in drug metabolism support screening for rare CYP3A4 functional alleles among subjects with adverse drug events in certain populations.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ethnicity / Polymorphism, Single Nucleotide / Cytochrome P-450 CYP3A / Gene Frequency Limits: Humans Language: En Journal: Pharmacogenomics J Journal subject: BIOLOGIA MOLECULAR / FARMACOLOGIA Year: 2015 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ethnicity / Polymorphism, Single Nucleotide / Cytochrome P-450 CYP3A / Gene Frequency Limits: Humans Language: En Journal: Pharmacogenomics J Journal subject: BIOLOGIA MOLECULAR / FARMACOLOGIA Year: 2015 Document type: Article Affiliation country:
...